{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:49:10Z","timestamp":1793033350570,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006197","name":"Fonden til L\u00e6gevidenskabens Fremme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bone.2022.116417","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T12:18:00Z","timestamp":1649333880000},"page":"116417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats"],"prefix":"10.1016","volume":"160","author":[{"given":"Mikkel Bo","family":"Brent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Br\u00fcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Skovhus","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2022.116417_bb0005","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2022.116417_bb0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0378-5122(98)00090-5","article-title":"Risk factors in osteoporosis","volume":"30","author":"Kanis","year":"1998","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2022.116417_bb0015","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.1996.00440120051005","article-title":"Osteoporosis: frequency, consequences, and risk factors","volume":"156","author":"Ross","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2022.116417_bb0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00223-020-00799-9","article-title":"A systematic review of animal models of disuse-induced bone loss","volume":"108","author":"Brent","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2022.116417_bb0025","first-page":"250","article-title":"Bone atrophy. An experimental and clinical study of the changes in bone which result from non\u2212use.","volume":"33","author":"Allison","year":"1921","journal-title":"SurgeryGynecol. Obstet."},{"key":"10.1016\/j.bone.2022.116417_bb0030","series-title":"Arch. F\u00fcr Die Gesamte Physiol. Des Menschen Und Der Tiere","first-page":"361","article-title":"Ueber den Einfluss der Nervendurchschneidung auf die Ern\u00e4hrung, insbesondere auf die Form und die Zusammensetzung der Knochen","volume":"23","author":"Nasse","year":"1880"},{"key":"10.1016\/j.bone.2022.116417_bb0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2022.116417_bb0040","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/\u03b2-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2022.116417_bb0045","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2022.116417_bb0050","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1359\/jbmr.090411","article-title":"Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt\/\u03b2-catenin signaling","volume":"24","author":"Lin","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116417_bb0055","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1210\/jc.2010-0067","article-title":"Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss","volume":"95","author":"Gaudio","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2022.116417_bb0060","doi-asserted-by":"crossref","first-page":"16744","DOI":"10.1074\/jbc.M114.628313","article-title":"The wnt inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in vitro","volume":"290","author":"Spatz","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2022.116417_bb0065","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2022.116417_bb0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00223-018-0439-8","article-title":"Sclerostin antibody reverses the severe sublesional bone loss in rats after chronic spinal cord injury","volume":"103","author":"Zhao","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2022.116417_bb0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2016.02.005","article-title":"Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse","volume":"87","author":"Zhang","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174409","article-title":"Abaloparatide: a review of preclinical and clinical studies","volume":"909","author":"Brent","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bone.2022.116417_bb0090","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0149-2918(04)90128-2","article-title":"Teriparatide: a review","volume":"26","author":"Quattrocchi","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2022.116417_bb0095","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1359\/jbmr.090730","article-title":"Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice","volume":"25","author":"Kramer","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116417_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115801","article-title":"Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading","volume":"144","author":"Teguh","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0105","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1152\/japplphysiol.01622.2005","article-title":"Disuse in adult male rats attenuates the bone anabolic response to a therapeutic dose of parathyroid hormone","volume":"101","author":"Turner","year":"2006","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.bone.2022.116417_bb0110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S8756-3282(00)00438-5","article-title":"Texture analysis of X-ray radiographs is a more reliable descriptor of bone loss than mineral content in a rat model of localized disuse induced by the clostridium botulinum toxin","volume":"28","author":"Chappard","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2020.101079","article-title":"Rodent model of disuse-induced bone loss by hind limb injection with botulinum toxin a","volume":"7","author":"Brent","year":"2020","journal-title":"MethodsX."},{"key":"10.1016\/j.bone.2022.116417_bb0120","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3389\/fendo.2020.588773","article-title":"The efficacy of PTH and abaloparatide to counteract immobilization-induced osteopenia is in general similar","volume":"11","author":"Brent","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bone.2022.116417_bb0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bone.2005.08.009","article-title":"Botox induced muscle paralysis rapidly degrades bone","volume":"38","author":"Warner","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0130","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116417_bb0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bone.2018.02.017","article-title":"PTH (1\u201334) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats","volume":"110","author":"Brent","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0140","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116417_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2012.11.037","article-title":"PTH (1\u201334), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats","volume":"53","author":"Br\u00fcel","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0150","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115183","article-title":"Disuse-induced loss of bone mineral density and bone strength is attenuated by post-lactational bone gain in NMRI mice","volume":"131","author":"S\u00f8rensen","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115692","article-title":"Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice","volume":"142","author":"Brent","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/ham.2020.0164","article-title":"The effect of normobaric intermittent hypoxia therapy on bone in normal and disuse osteopenic mice","volume":"22","author":"Bromer","year":"2021","journal-title":"High Alt. Med. Biol."},{"key":"10.1016\/j.bone.2022.116417_bb0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/toxins13030213","article-title":"Botulinum toxin a and osteosarcopenia in experimental animals: a scoping review","volume":"13","author":"Tang","year":"2021","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.bone.2022.116417_bb0175","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fendo.2021.628994","article-title":"Teriparatide and abaloparatide have a similar effect on bone in mice","volume":"12","author":"Brent","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bone.2022.116417_bb0180","article-title":"Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: a comparison with teriparatide","volume":"142","author":"Makino","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0185","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jbmr.3930","article-title":"Abaloparatide at the same dose has the same effects on bone as PTH (1\u201334) in mice","volume":"35","author":"Le Henaff","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116417_bb0190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2022.116417_bb0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2022.116417_bb0200","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1074\/jbc.RA118.004751","article-title":"Parathyroid hormone(1\u201334) and its analogs differentially modulate osteoblastic rankl expression via PKA\/SIK2\/SIK3 and PP1\/PP2A\u2013CRTC3 signaling","volume":"293","author":"Ricarte","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2022.116417_bb0205","article-title":"Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis","volume":"9","author":"Tella","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.bone.2022.116417_bb0210","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.bone.2022.116417_bb0215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00391-019-01685-2","article-title":"Combined antisclerostin antibody and parathyroid hormone (1\u201334) synergistically enhance the healing of bone defects in ovariectomized rats","volume":"53","author":"Lin","year":"2020","journal-title":"Z. Gerontol. Geriatr."},{"key":"10.1016\/j.bone.2022.116417_bb0220","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116417_bb0225","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.tem.2009.12.002","article-title":"Does osteocytic SOST suppression mediate PTH bone anabolism?","volume":"21","author":"Kramer","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bone.2022.116417_bb0230","article-title":"Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series","author":"Ruiz-Villaverde","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.bone.2022.116417_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106595","article-title":"Efficacy of mepolizumab in usual clinical practice and characteristics of responders: mepolizumab in usual clinical practice","volume":"187","author":"Rodr\u00edguez-Garc\u00eda","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.bone.2022.116417_bb0240","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2022.116417_bb0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822200093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822200093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:43:33Z","timestamp":1762659813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822200093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":49,"alternative-id":["S875632822200093X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116417","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116417"}}